The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors

• Published in: Cancer letters 2005-01, Vol.217 (1), p.73-86
• Main Authors: Azenshtein, Elina, Meshel, Tsipi, Shina, Sima, Barak, Nely, Keydar, Iafa, Ben-Baruch, Adit
• Format: Article
• Language: English
• Subjects: Angiogenesis; Breast cancer; Breast Neoplasms - metabolism; CCL2; CCL5; Cell growth; Cell Line, Tumor; Chemokine CCL2 - pharmacology; Chemokine CCL5; Chemokines; Chemokines, CC - pharmacology; CXCL8; EGF; Enzyme-Linked Immunosorbent Assay; Epidermal growth factor; Epidermal Growth Factor - pharmacology; Estrogens - pharmacology; Hormones; Humans; Interleukin-8 - metabolism; Medical prognosis; Medical research; Migration; Monocytes - metabolism; Neovascularization, Pathologic - metabolism; Progesterone - pharmacology; Reverse Transcriptase Polymerase Chain Reaction; Tumors; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - drug effects; Vascular Endothelial Growth Factor A - metabolism; VEGF
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2004.05.024

The regulation of secretion of the angiogenic factors CXCL8 and Vascular Endothelial Growth Factors (VEGF) was determined in breast tumor cells and in monocytic cells (as host cells that contribute to breast cancer). CXCL8 secretion, and partly the secretion of VEGF, were up-regulated in monocytic cells, but not in breast tumor cells, by the CC chemokines CCL5 and CCL2. EGF potently up-regulated CXCL8 secretion by breast tumor cells, and its effect was promoted by a consecutive treatment of the cells by estrogen and progesterone. These findings provide evidence for a complex set of pro-malignancy factors that may control the expression of angiogenic mediators at breast tumor sites.